Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Current Liabilities: 2015-2024

Historic Total Current Liabilities for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $103.5 million.

  • Syndax Pharmaceuticals' Total Current Liabilities rose 92.31% to $114.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.2 million, marking a year-over-year increase of 92.31%. This contributed to the annual value of $103.5 million for FY2024, which is 78.24% up from last year.
  • According to the latest figures from FY2024, Syndax Pharmaceuticals' Total Current Liabilities is $103.5 million, which was up 78.24% from $58.1 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Total Current Liabilities ranged from a high of $103.5 million in FY2024 and a low of $18.9 million during FY2020.
  • In the last 3 years, Syndax Pharmaceuticals' Total Current Liabilities had a median value of $58.1 million in 2023 and averaged $63.6 million.
  • Data for Syndax Pharmaceuticals' Total Current Liabilities shows a peak YoY soared of 99.88% (in 2023) over the last 5 years.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Current Liabilities (Yearly) stood at $18.9 million in 2020, then increased by 9.60% to $20.7 million in 2021, then spiked by 40.53% to $29.1 million in 2022, then skyrocketed by 99.88% to $58.1 million in 2023, then spiked by 78.24% to $103.5 million in 2024.